Fig. 1: SRPK1 overexpression is associated with gefitinib resistance in NSCLC patients. | Oncogene

Fig. 1: SRPK1 overexpression is associated with gefitinib resistance in NSCLC patients.

From: Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer

Fig. 1

A Representative images of IHC staining of SRPK1 in lung tissue sections from NSCLC patients (left; n = 65), and quantitative analysis of SRPK1 staining (right); scale bars: 20 μm. Data represent the mean optical density (MOD) ± SD (n = 10, 2-tailed Student’s t test). The whiskers represent 5 and 95 percentiles. B Kaplan-Meier curves for estimation of PFS in NSCLC patients with high- or low- SRPK1 expression (Log-rank test). C Pearson chi-squared (χ2) test analysis of the relationship between PFS and SRPK1 expression; the number of NSCLC patients is shown. D Analyses of SRPK1 gene expression in NSCLC cell lines in publicly available datasets (NCBI/GEO/GSE 14925, NCBI/GEO/GSE 47206, and NCBI/ GEO/GSE 34228). E qRT-PCR analysis and (F) Western blot analysis of SRPK1 expression in PC9, NCI-H1650, PC9GR, and NCI-H1975 cells. Data represent the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page